AllianceBernstein’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.8M Buy
44,641
+322
+0.7% +$110K 0.01% 968
2025
Q4
$17.6M Buy
44,319
+543
+1% +$240K 0.01% 997
2025
Q3
$20M Sell
43,776
-23,355
-35% -$9.51M 0.01% 919
2025
Q2
$21.9M Buy
67,131
+22,294
+50% +$6.17M 0.01% 871
2025
Q1
$12.1M Buy
44,837
+247
+0.6% +$63.5K ﹤0.01% 1074
2024
Q4
$10.5M Sell
44,590
-8,034
-15% -$2.11M ﹤0.01% 1167
2024
Q3
$14.5M Buy
52,624
+7,251
+16% +$1.89M ﹤0.01% 1014
2024
Q2
$11M Sell
45,373
-8,803
-16% -$1.39M ﹤0.01% 1120
2024
Q1
$8.1M Sell
54,176
-466,663
-90% -$77.8M ﹤0.01% 1264
2023
Q4
$99.7M Sell
520,839
-19,867
-4% -$3.38M 0.04% 406
2023
Q3
$95.8M Sell
540,706
-9,573
-2% -$1.83M 0.04% 396
2023
Q2
$105M Buy
550,279
+14,320
+3% +$2.84M 0.04% 378
2023
Q1
$107M Buy
535,959
+464,775
+653% +$97.7M 0.05% 368
2022
Q4
$16.9M Sell
71,184
-3,784
-5% -$807K 0.01% 887
2022
Q3
$15M Sell
74,968
-600,039
-89% -$114M 0.01% 925
2022
Q2
$98.5M Buy
675,007
+618,470
+1,094% +$87.7M 0.05% 375
2022
Q1
$9.23M Sell
56,537
-13,343
-19% -$2.03M ﹤0.01% 1285
2021
Q4
$11.8M Buy
69,880
+3,194
+5% +$594K ﹤0.01% 1159
2021
Q3
$12.6M Buy
66,686
+4,765
+8% +$894K 0.01% 1124
2021
Q2
$10.5M Sell
61,921
-5,798
-9% -$849K ﹤0.01% 1214
2021
Q1
$9.56M Sell
67,719
-55,758
-45% -$8.39M ﹤0.01% 1226
2020
Q4
$16M Buy
123,477
+56,687
+85% +$7.57M 0.01% 934
2020
Q3
$9.72M Sell
66,790
-10,901
-14% -$1.55M 0.01% 1051
2020
Q2
$11.5M Buy
77,691
+4,490
+6% +$605K 0.01% 939
2020
Q1
$7.97M Sell
73,201
-54,587
-43% -$6.3M 0.01% 998
2019
Q4
$14.7M Buy
127,788
+12,645
+11% +$1.26M 0.01% 919
2019
Q3
$9.26M Buy
115,143
+11,272
+11% +$892K 0.01% 1085
2019
Q2
$7.54M Buy
103,871
+55,080
+113% +$4.23M ﹤0.01% 1180
2019
Q1
$4.56M Sell
48,791
-199
-0.4% -$16.6K ﹤0.01% 1427
2018
Q4
$3.57M Sell
48,990
-698
-1% -$53.7K ﹤0.01% 1488
2018
Q3
$4.35M Sell
49,688
-1,640
-3% -$165K ﹤0.01% 1383
2018
Q2
$5.05M Buy
51,328
+2,045
+4% +$203K ﹤0.01% 1233
2018
Q1
$5.87M Buy
49,283
+3,830
+8% +$494K ﹤0.01% 1129
2017
Q4
$5.78M Buy
45,453
+1,680
+4% +$211K ﹤0.01% 1146
2017
Q3
$5.14M Sell
43,773
-4,100
-9% -$350K ﹤0.01% 1194
2017
Q2
$3.82M Buy
47,873
+398
+0.8% +$25.4K ﹤0.01% 1369
2017
Q1
$2.43M Sell
47,475
-330
-0.7% -$15.3K ﹤0.01% 1669
2016
Q4
$1.79M Sell
47,805
-2,259
-5% -$94.6K ﹤0.01% 1915
2016
Q3
$3.39M Sell
50,064
-150
-0.3% -$10.6K ﹤0.01% 1378
2016
Q2
$2.79M Buy
50,214
+600
+1% +$37.8K ﹤0.01% 1436
2016
Q1
$3.11M Sell
49,614
-325
-0.7% -$21.6K ﹤0.01% 1293
2015
Q4
$4.7M Sell
49,939
-1,185
-2% -$110K ﹤0.01% 1085
2015
Q3
$4.11M Sell
51,124
-861
-2% -$95.7K ﹤0.01% 1147
2015
Q2
$6.23M Buy
51,985
+3,477
+7% +$416K 0.01% 1027
2015
Q1
$5.07M Buy
48,508
+2,970
+7% +$301K ﹤0.01% 1117
2014
Q4
$4.42M Buy
45,538
+3,900
+9% +$361K ﹤0.01% 1174
2014
Q3
$3.25M Buy
41,638
+500
+1% +$32.3K ﹤0.01% 1365
2014
Q2
$2.6M Sell
41,138
-74,812
-65% -$4.45M ﹤0.01% 1585
2014
Q1
$7.79M Sell
115,950
-5,426
-4% -$420K 0.01% 935
2013
Q4
$7.81M Sell
121,376
-1,972
-2% -$118K 0.01% 929
2013
Q3
$7.9M Buy
123,348
+158
+0.1% +$7.88K 0.01% 898
2013
Q2
$3.82M Buy
+123,190
New +$3.28M ﹤0.01% 1153

Other funds holding ALNY

AllianceBernstein's ALNY Position: Q1 2026 in Review

AllianceBernstein increased its Alnylam Pharmaceuticals (ALNY) stake by 0.73% in Q1 2026, buying an estimated $110K and bringing the position to 44,641 shares worth $17.8M. The position accounts for 0.01% of the portfolio, ranked #968.

AllianceBernstein first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $107M in Q1 2023. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • AllianceBernstein held 44,641 shares of Alnylam Pharmaceuticals worth $17.8M as of Q1 2026.
  • AllianceBernstein bought 322 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $110K.
  • Alnylam Pharmaceuticals made up 0.01% of AllianceBernstein's portfolio in Q1 2026, its #968 holding.
  • AllianceBernstein first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Alnylam Pharmaceuticals position peaked at $107M in Q1 2023.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.